No abstract available
MeSH terms
-
Acute Disease
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Bone Marrow Transplantation / adverse effects*
-
Bone Marrow Transplantation / methods
-
Bone Marrow Transplantation / mortality
-
Busulfan / administration & dosage
-
Busulfan / adverse effects
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Carmustine / adverse effects
-
Clinical Trials, Phase I as Topic
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cystitis / chemically induced
-
Female
-
Hepatic Veno-Occlusive Disease / epidemiology
-
Hepatic Veno-Occlusive Disease / etiology
-
Hepatic Veno-Occlusive Disease / prevention & control
-
Hepatic Veno-Occlusive Disease / therapy
-
Humans
-
Incidence
-
Leukemia, Myeloid / therapy
-
Liver / drug effects
-
Liver / radiation effects
-
Lung Diseases, Interstitial / chemically induced
-
Lung Diseases, Interstitial / epidemiology
-
Lymphoma / therapy
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Retrospective Studies
-
Risk Factors
-
Whole-Body Irradiation / adverse effects*
Substances
-
Antineoplastic Agents
-
Cyclophosphamide
-
Carboplatin
-
Busulfan
-
Carmustine
-
Methotrexate